Home › NCT07217405
Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis
RecruitingPhase 4
Low-Dose Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis
Who can join
Ages 50 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patient at Mayo Clinic, Rochester, MN * Age 50 years or older * Mild, moderate, or severe hand OA (Kellgren and Lawrence classification grade 2, 3, or 4) on hand radiographs within the last 24 months * Hand OA pain with a minimum VAS score relating to hand pain of ≥40 (on a 100-point scale) when using the affected hand * Ability to complete study questionnaires Exclusion Criteria: * History of previous surgery to the affected hand(s) * Autoimmune joint disease such as rheumatoid arthritis or psoriatic arthritis * Active confounding hand condition such as stenosing tenosynovitis or Dupuytren's contracture * Recent injury (within last 1 month) to the affected hand causing current pain * History of crystalline arthritis (gout or pseudogout) flare in the affected hand(s) * Active use of opioid pain medication(s) or oral steroids within the last 3 months * Fibromyalgia or central sensitization syndrome * Hand CSI or other hand injection within the past 3 months * History of hand LDRT within the past 3 months * Poorly controlled diabetes (HbA1c \> 10%) * Active infection * Current pregnancy
About the study
The purpose of this research is to compare low-dose radiotherapy to corticosteroid injection for treatment of hand/wrist osteoarthritis.
What is being tested
- Corticosteroid injection (CSI) (drug)
- Low-dose radiotherapy (LDRT) (radiation)
Sponsor: Mayo Clinic · Participants: 165 · Started: Dec 19, 2025
Contact the study team
- Tochukwu Iyke-Nzeocha · Phone: (507) 422-3201
- Melissa Wang, M.A., CCRP · Phone: (507) 266-6911
Official record on ClinicalTrials.gov — NCT07217405
Locations in the U.S.
| Minnesota | Mayo Clinic in Rochester, Rochester |
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.